Literature DB >> 17564822

Minimal protein domain requirements for the intracellular localization and self-aggregation of Epstein-Barr virus latent membrane protein 2.

Monica Jo Tomaszewski-Flick1, David T Rowe.   

Abstract

The EBV Latent Membrane Protein 2 (LMP2) may have a role in the establishment and maintenance of in vivo latency. The gene is transcribed into two mRNAs that produce two LMP2 protein isoforms. The LMP2a protein isoform has 12 transmembrane segments (TMs) and an amino terminal cytoplasmic signaling domain (CSD) while the LMP2b isoform is identical but lacks the CSD. There has not been a consensus on the cellular membrane localization being sometimes ascribed to either a plasma membrane or an intracellular location [M. Rovedo, R. Longnecker, J. Virol. 81:89-94, 2007; D. Lynch, J. Zimmerman, D.T. Rowe, J. Gen. Virol. 83:1025-1035, 2002; C. Dawson, J. George, S. Blake, R. Longnecker, L.S. Young, Virology 289:192-207, 2001]. Fluorescent marker and epitope tagged LMP2b truncation mutants progressively removing TMs from the N and C termini were used to assess the localization and aggregation properties of LMP2b. wtLMP2b had an exclusively intracellular perinuclear localization, while all truncations of the protein resulted in localization to the cell surface. By epitope loop-tagging, all the truncated LMP2b proteins were verified to be in the predicted membrane orientation. In co-transfection experiments, the C-terminal region was implicated in the self-aggregation properties of LMP2b. Thus, an intact 12 TM domain was required for intracellular localization and protein-protein interaction while a C-terminal region was responsible for auto-aggregative properties.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17564822     DOI: 10.1007/s11262-007-0118-8

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  25 in total

1.  The trans-Golgi network GRIP-domain proteins form alpha-helical homodimers.

Authors:  Michael R Luke; Fiona Houghton; Matthew A Perugini; Paul A Gleeson
Journal:  Biochem J       Date:  2005-06-15       Impact factor: 3.857

2.  Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell.

Authors:  E M Miyashita; B Yang; G J Babcock; D A Thorley-Lawson
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

3.  In vivo growth of Epstein-Barr virus transformed B cells with mutations in latent membrane protein 2 (LMP2).

Authors:  R Rochford; C L Miller; M J Cannon; K M Izumi; E Kieff; R Longnecker
Journal:  Arch Virol       Date:  1997       Impact factor: 2.574

4.  Role of Epstein-Barr virus-encoded latent membrane protein 2A on virus-induced immortalization and virus activation.

Authors:  Kazuya Konishi; Seiji Maruo; Hiroyuki Kato; Kenzo Takada
Journal:  J Gen Virol       Date:  2001-06       Impact factor: 3.891

5.  An Epstein-Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase.

Authors:  R Longnecker; B Druker; T M Roberts; E Kieff
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

6.  The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction.

Authors:  S Fruehling; R Longnecker
Journal:  Virology       Date:  1997-09-01       Impact factor: 3.616

7.  Epstein-Barr virus lacking latent membrane protein 2 immortalizes B cells with efficiency indistinguishable from that of wild-type virus.

Authors:  Peter Speck; Kimberly A Kline; Paul Cheresh; Richard Longnecker
Journal:  J Gen Virol       Date:  1999-08       Impact factor: 3.891

8.  Lysine-independent ubiquitination of Epstein-Barr virus LMP2A.

Authors:  Masato Ikeda; Akiko Ikeda; Richard Longnecker
Journal:  Virology       Date:  2002-08-15       Impact factor: 3.616

9.  Epstein-Barr virus coopts lipid rafts to block the signaling and antigen transport functions of the BCR.

Authors:  M L Dykstra; R Longnecker; S K Pierce
Journal:  Immunity       Date:  2001-01       Impact factor: 31.745

10.  Itchy, a Nedd4 ubiquitin ligase, downregulates latent membrane protein 2A activity in B-cell signaling.

Authors:  Akiko Ikeda; Robert G Caldwell; Richard Longnecker; Masato Ikeda
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

View more
  6 in total

Review 1.  Virus-Mediated Inhibition of Apoptosis in the Context of EBV-Associated Diseases: Molecular Mechanisms and Therapeutic Perspectives.

Authors:  Zbigniew Wyżewski; Matylda Barbara Mielcarska; Karolina Paulina Gregorczyk-Zboroch; Anna Myszka
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

2.  Latent membrane protein 2B regulates susceptibility to induction of lytic Epstein-Barr virus infection.

Authors:  Markus P Rechsteiner; Christoph Berger; Ludwig Zauner; Jürg A Sigrist; Matthias Weber; Richard Longnecker; Michele Bernasconi; David Nadal
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

Review 3.  Epstein-Barr virus latent genes.

Authors:  Myung-Soo Kang; Elliott Kieff
Journal:  Exp Mol Med       Date:  2015-01-23       Impact factor: 8.718

4.  Identification and characterization of a novel Epstein-Barr Virus-encoded circular RNA from LMP-2 Gene.

Authors:  Ke-En Tan; Wei Lun Ng; Georgi K Marinov; Ken Hung-On Yu; Lu Ping Tan; Ee Shan Liau; Sook Yan Goh; Kok Siong Yeo; Kevin Y Yip; Kwok-Wai Lo; Alan Soo-Beng Khoo; Lee-Fah Yap; Chee-Kwee Ea; Yat-Yuen Lim
Journal:  Sci Rep       Date:  2021-07-13       Impact factor: 4.379

5.  EBV infection is common in gingival epithelial cells of the periodontium and worsens during chronic periodontitis.

Authors:  Séverine Vincent-Bugnas; Sébastien Vitale; Caroline C Mouline; Wafa Khaali; Yves Charbit; Patrick Mahler; Isabelle Prêcheur; Paul Hofman; Janet L Maryanski; Alain Doglio
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

6.  Novel EBV LMP-2-affibody and affitoxin in molecular imaging and targeted therapy of nasopharyngeal carcinoma.

Authors:  Shanli Zhu; Jun Chen; Yirong Xiong; Saidu Kamara; Meiping Gu; Wanlin Tang; Shao Chen; Haiyan Dong; Xiangyang Xue; Zhi-Ming Zheng; Lifang Zhang
Journal:  PLoS Pathog       Date:  2020-01-06       Impact factor: 6.823

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.